Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Tools

Item Type:	Letter
Title:	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Creators Name:	Dang, N.H., Ogura, M., Castaigne, S., Fayad, L.E., Jerkeman, M., Radford, J., Pezzutto, A., Bondarenko, I., Stewart, D.A., Shnaidman, M., Sullivan, S., Vandendries, E., Tobinai, K., Ramchandren, R., Hamlin, P.A., Giné, E. and Ando, K.
Keywords:	Inotuzumab Ozogamicin, B-Cell Non-Hodgkin Lymphoma, CD22+, Antibody-Drug Conjugate, Rituximab
Source:	British Journal of Haematology
ISSN:	0007-1048
Publisher:	Wiley-Blackwell
Volume:	182
Number:	4
Page Range:	583-586
Date:	August 2018
Official Publication:	https://doi.org/10.1111/bjh.14820
External Fulltext:	View full text on PubMed Central
PubMed:	View item in PubMed

Repository Staff Only: item control page